re perspective, page-23

I'm still around. Reading occasionally, but not really time to post at the moment.

Every time some bad news comes through (as it does from time to time for most companies) it seems to set off a few really annoying 'told you so', 'smarty pants' type posters who are nit pickers with nothing decent to say and who just seem to 'get off' on negativity.

It just puts you off the whole process for a while!

But, having said that, there have been some really good posts. Great to see the thread still alive, despite the difficulties.

SSV and AJ have hit the nail on the head a couple of times.

It seems to me the situation is pretty simple.

The scenario looked pretty good. We seemed to be heading solidly towards break-even point. The threefold increase in Oraline sales from the previous Qtr was impressive. The Company had turned in a significant increase in sales - essentially from one product being sold into restricted markets, mainly in the US.

Why was this good? Because if SBN could move so vigorously towards b/even with just O/IV, how would it be going come the end of the Sept Qtr - with Oraline 8, Visualine and the Bioscreens device all released by then. As well as the possibility of sales into Mexico and the likelihood that sales into Russia, UK and China were only a few months away.

So with the Chairman's blunt announcement came a blow to the expectations. Not only of increasing the speed of movement to b/e, but also in underpinning a (necessary) capital raising at favourable terms.

I believe the Chairman's statement relates to a blip and not a trend. The success of the company in recruiting new distributors was clearly reflected in the March Qtr. This in fact broke a trend decisively. This, apparently, is not to be repeated in the current Qtr. But the statement did not say that the results would go back to where they were in the Dec Qtr. I doubt that would happen.

The setback probably reflects the fact that the distributors who bought up earlier in the year have not been moving enough of the product to repeat orders and maintain the rate of sales increase. As well the continuing recruitment of distributors has not offset this. However, this will not last. Many who do not reorder this Qtr may next. And the build up of distributors is continiuing apace - in many corners of the globe. And this should start to show up in the bottom line as well. And late in the Sept Qtr, sales of the recently launched Oraline 8 and urine devices will start to be brought to account.

So even before China, Russia and Mexico, organic growth from the soon-to-be-increased range should move us back in the right direction. This will provide a good platform for the big breakthroughs when they come. I have always and continue to believe that China alone will make something significant of this company.(No civil libertarians, no competition).

In the short term, though, we have the cap raising. And there is nothing unusual in what has happened to the SP given this context. There are multiple reasons for that and you know what those are.

It's just a matter of suffering the pain and, if you can, take advantage of the bargain basement offer when it comes.

Just like last year - following the 1.3c issue. With that out of the way the market could concentrate on the business prospects and, rightly or wrongly, the SP took off on the prospects (of Mexico and FDA clearance).

This time round, there are many more prospects to cause that boost - and arguably less speculative (particularly if and after China accepts the new specification work on Oraline due to be delivered next month). Not to mention the FACT that Oraline has been used in the Mexico trial AND the Russian approval processes are tracking ahead of schedule and the company will have the $ to commercialise all its new ventures.

Good luck to all - and now back to my hibernation.